# Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Study · id `cardio:ct-nct07090161` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07090161](<https://clinicaltrials.gov/study/NCT07090161>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07090161

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT07090161. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-15 (actual); primary completion 2026-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT07090161, source copy `cardio:ctgov-nct07090161-2026-02-27`, retrieved 2026-10-26)
- Started: 2025-09-15 (actual) (ClinicalTrials.gov record NCT07090161, source copy `cardio:ctgov-nct07090161-2026-02-27`, retrieved 2026-10-26)
- Primary completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07090161, source copy `cardio:ctgov-nct07090161-2026-02-27`, retrieved 2026-10-26)
- Completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07090161, source copy `cardio:ctgov-nct07090161-2026-02-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07090161, source copy `cardio:ctgov-nct07090161-2026-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07090161-2026-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
- Condition: Hypertension
- Condition: Uncontrolled Hypertension
- Intervention (Drug): iloperidone
- Intervention (Drug): Placebo
- Lead sponsor: Vanda Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 843696df29805074454faa40faa423b1cf0e86f717f03196b0cd8bb2e1691bec
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
